J B Chemicals and Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about J B Chemicals and Pharmaceuticals

CCI Approves Torrent Pharma's Acquisition of J.B. Chemicals with Conditions Oct 21, 2025

The Competition Commission of India (CCI) has granted conditional approval for Torrent Pharmaceuticals to acquire J B Chemicals and Pharmaceuticals. This decision is a significant step in the consolidation of the Indian pharmaceutical sector. The approval comes with undisclosed conditions, likely aimed at ensuring fair competition. This acquisition could potentially reshape the competitive landscape in the Indian pharmaceutical industry, strengthening Torrent Pharma's market position.

Torrent Pharmaceuticals Issues Corrigendum for ₹6,842.80 Crore Open Offer to J.B. Chemicals Shareholders Sep 04, 2025

JB Chemicals Strengthens Leadership with Key Board Appointments and CEO Re-election Aug 06, 2025

J.B. Chemicals Reports 9% Revenue Growth, Record EBITDA Margins in Q1 Aug 05, 2025

JB Pharma Reports Robust Q1 Results with 14% Revenue Growth in Domestic Business Jul 30, 2025

More news about J B Chemicals and Pharmaceuticals

30Jul 25

JB Chemicals & Pharma Reports Robust Q1 FY26 Performance with 9% Revenue Growth

JB Chemicals and Pharmaceuticals reported robust Q1 FY26 results with revenue increasing 9% to ₹1,094.00 crore. Operating EBITDA grew 13% to ₹330.00 crore, and net profit rose 14% to ₹202.00 crore. The domestic formulations business saw 14% growth, while the international business grew 2%. The company maintained its position as the fastest-growing among the top 25 pharmaceutical firms in India. JB Pharma also entered into a share purchase agreement with Torrent Pharmaceuticals, potentially leading to a merger.

04Jul 25

J.B. Chemicals & Pharmaceuticals Sees Major Block Trade on NSE

A significant block trade of approximately 511,235 shares of J B Chemicals and Pharmaceuticals occurred on the National Stock Exchange. The transaction was executed at Rs. 1,639.00 per share, totaling Rs. 83.79 crores. This large trade indicates substantial investor interest and could potentially signal shifts in ownership or market sentiment towards the company.

03Jul 25

J.B. Chemicals & Pharmaceuticals Sees Significant Block Trade on NSE

A significant block trade of approximately 100,280 shares of J.B. Chemicals & Pharmaceuticals occurred on the National Stock Exchange (NSE). The transaction was valued at Rs. 16.44 crore, with each share priced at Rs. 1,639.50. This large-scale trade has attracted attention from market observers and investors, potentially signaling shifts in institutional holdings or strategic moves by large investors in the pharmaceutical sector.

24Jun 25

JB Chemicals Secures US FDA Approval for Generic Antidepressant

J B Chemicals and Pharmaceuticals has received final FDA approval for Amitriptyline Hydrochloride Tablets USP, a generic antidepressant, in various dosages. This approval allows the company to enter the U.S. market with a widely-used depression medication, potentially boosting its international growth and revenue. The move aligns with increasing global demand for mental health medications and positions J B Chemicals to offer a cost-effective alternative in the U.S. pharmaceutical market.

16May 25

JB Chemicals & Pharma Raises Operating Margin Guidance, Sets Ambitious Sales Target

JB Chemicals & Pharmaceuticals Limited has increased its EBITDA margin guidance to 27-29% for the third consecutive year. The company aims to achieve a monthly sales run rate of nearly 140,000 units by the end of H1. These updates were shared during a recent conference call, indicating management's confidence in the company's performance and growth prospects.

14May 25

JB Chemicals & Pharmaceuticals: Q4 FY2025 Profit and Revenue Meet Estimates, Showing Strong Growth

J.B. Chemicals & Pharmaceuticals announced its Q4 FY2025 results, reporting a 16% year-over-year increase in consolidated net profit to ₹146.00 crore. Revenue grew by 10% to ₹949.00 crore. The company's domestic formulations business saw an 11% revenue increase to ₹519.00 crore, while international operations revenue rose by 9% to ₹430.00 crore. The CDMO business also contributed significantly to overall growth.

21Apr 25

J.B. Chemicals & Pharmaceuticals Secures FDA Approval for Hypertension Drug

J.B. Chemicals & Pharmaceuticals has received USFDA approval for its Abbreviated New Drug Application (ANDA) of Bisoprolol Tablets, a generic version of Zebeta used to treat hypertension. This approval marks a significant milestone in the company's expansion into the U.S. market, potentially strengthening its position and offering a cost-effective alternative for patients. Bisoprolol, a beta-blocker, works by blocking certain natural chemicals in the body to decrease heart rate and blood pressure.

19Apr 25

J.B. Chemicals & Pharmaceuticals Secures FDA Approval for Generic Hypertension Drug

J.B. Chemicals & Pharmaceuticals has obtained FDA approval for its Abbreviated New Drug Application (ANDA) of Bisoprolol tablets, a generic version of the hypertension drug Zebeta. This approval allows the company to enter the U.S. cardiovascular therapeutics market, potentially boosting its revenue and expanding its product portfolio. The move signifies J.B. Chemicals' commitment to growth in regulated markets and demonstrates its ability to meet international quality standards.

18Apr 25

JB Chemicals Secures FDA Approval for Generic Hypertension Drug

JB Chemicals and Pharmaceuticals Ltd. has received USFDA approval for its generic version of Bisoprolol tablets in 5 mg and 10 mg strengths, equivalent to Teva's Zebeta tablets. This approval marks a significant step in the company's expansion into the U.S. market, potentially offering a more affordable alternative for hypertension treatment. Bisoprolol, a beta-blocker used for high blood pressure and certain heart conditions, represents an important addition to JB Chemicals' product portfolio in the cardiovascular drug market.

02Apr 25

JB Chemicals Invests ₹70 Million in Renewable Energy Venture

JB Chemicals and Pharmaceuticals Limited has approved a ₹70 million investment to acquire shares in Jamnagar Renewables One, marking its entry into the renewable energy sector. This strategic move represents a diversification from the company's core pharmaceutical business and aligns with growing trends in sustainability among pharmaceutical companies.

27Mar 25

JB Chemicals & Pharmaceuticals Shares Tumble as Promoter Offloads 5.8% Stake for ₹1,460 Crore

Tau Investment Holdings, a promoter of JB Chemicals & Pharmaceuticals, sold 89.83 lakh shares (5.80% stake) at ₹1,625 per share, totaling ₹1,460 crore. Kotak Mahindra Mutual Fund acquired 12.3 lakh shares (0.79% stake). The stock closed at ₹1,615.70 on NSE, down 5.45% following the news.

27Mar 25

KKR to Offload Up to 10.2% Stake in JB Chemicals & Pharmaceuticals for ₹2,576 Crore

Global investment firm KKR plans to reduce its holdings in JB Chemicals & Pharmaceuticals through a block deal worth ₹2,576 crore ($300 million). The sale includes a base offer of 6.8% stake and a greenshoe option of 3.4%. The floor price is set at ₹1,625 per share, a 4.9% discount to the previous closing price. This move aligns with KKR's investment cycle and portfolio management strategies, potentially reshaping JB Chemicals' ownership structure.

26Mar 25

KKR to Offload Up to 10.2% Stake in JB Chemicals for $300 Million

KKR plans to reduce its stake in JB Chemicals & Pharmaceuticals Ltd through a block deal. The sale includes a base offer of 6.8% stake ($200 million) and an oversubscription option of 3.4% ($100 million). The floor price is set at ₹1,708.75 per share, a 4.9% discount to the previous closing price.

26Mar 25

KKR Affiliate to Offload 10.2% Stake in JB Chemicals & Pharmaceuticals

TAU Investment, a promoter entity linked to KKR, plans to sell up to 10.2% stake (1.59 crore shares) in JB Chemicals & Pharmaceuticals through block deals. The floor price is set at Rs 1,625.00 per share, with an estimated deal size of Rs 2,575.00 crores. Kotak and IIFL are appointed as brokers for this transaction. This move comes after KKR acquired a controlling stake in the company in 2020.

17Mar 25

J.B. Chemicals & Pharma's API Facility Clears USFDA Inspection with Flying Colors

J.B. Chemicals & Pharmaceuticals Limited's API manufacturing facility D9 in Panoli, Gujarat, successfully cleared a four-day USFDA inspection from March 10-13, 2025, with no observations or Form 483 issued. This flawless outcome demonstrates the company's compliance with FDA regulations and commitment to high-quality standards in API production for the U.S. market.

14Mar 25

J.B. Chemicals & Pharma's API Facility Aces USFDA Inspection with Zero Observations

J.B. Chemicals & Pharmaceuticals Limited's D9 API manufacturing facility in Gujarat passed a USFDA inspection conducted from March 10-13, 2025, with no observations or Form 483 issued. The company reaffirmed its commitment to quality and compliance standards. This outcome could potentially boost JBCPL's API exports to the US, enhance its global reputation, and strengthen confidence in its quality management systems.

10Mar 25

J.B. Chemicals' Panoli Facility Passes USFDA Inspection with Flying Colors

J.B. Chemicals & Pharmaceuticals Ltd.'s Panoli facility successfully passed a United States Food and Drug Administration (USFDA) inspection with no observations noted. No Form 483 was issued, indicating full compliance with regulatory standards. This outcome enhances the company's credibility, potentially boosting market confidence and opening opportunities for expansion in the U.S. pharmaceutical market.